arrow
A

Adlinda Alip

University of Malaya
H指数:12
被引数:1,315

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
2026-02-040
PRE
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

携带EGFR突变型晚期非小细胞肺癌患者使用amivantamab-lazertinib的总体生存率

2025-09-019
PRE
Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline APOBEC3B deletion: results of the phase II AUROR study

帕博利珠单抗单药治疗既往接受过治疗的HER2阴性转移性乳腺癌(携带胚系APOBEC3B基因缺失):AUROR研究II期结果

2025-07-130
OA
Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

拉泽替尼与奥希替尼在先前未经治疗的EGFR突变晚期NSCLC中的比较: 来自MARIPOSA的随机,双盲,探索性分析

2025-07-030
OAAI
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Amivantamab联合Lazertinib治疗先前未经治疗的EGFR突变的晚期NSCLC

2024-10-2425
PRE
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Amivantamab联合lazertinib与osimertinib治疗具有高危疾病生物标志物的一线EGFR突变晚期非小细胞肺癌: 来自MARIPOSA的二次分析

2024-09-015
OAAI
Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

Amivantamab联合lazertinib与osimertinib作为EGFR突变的晚期非小细胞肺癌 (NSCLC) 患者的一线治疗: MARIPOSA,一项III期,全球,随机,对照试验的主要结果

2023-10-0141
OA
Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel
2021-02-231
OAAI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

泛亚适应ESMO临床实践指南,用于管理局部晚期不可切除的非小细胞肺癌患者: CSCO,ISMPO,JSMO,MOS,SSO和TOS认可的ksmo-esmo倡议

2020-02-0176
OAAI
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

EGFR突变型晚期NSCLC患者一线阿法替尼的真实世界经验: 一项多中心观察性研究

2019-09-0934
OAAI
Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017

中等收入国家晚期前列腺癌的管理: 2017晚期前列腺癌共识会议的现实思考

2019-06-1713
OAAI
Prospective, non-randomised, open-label study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy
2015-09-010
PREAI